Novel use of low-dose cidofovir (2.5 mg/kg Weekly) as CMV prophylaxis in the pre-engraftment Phase of stem cell transplantation: A viable alternative when ganciclovir is contraindicated and letermovir is not available (ASH 2025) - Dec 5, 2025 - "These include CMV-seropositive recipients (R+) with seronegative donors (D-) who are deemed to be at highest risk of CMV infection due to latent virus reactivation, those with previous CMV infections and in haploidentical BMT cases where Post Transplant Cyclophosphamide (PTCy) was used as GVHD prophylaxis. Low-dose weekly cidofovir represents a novel, cost-effective, and practical approach for CMV prophylaxis and treatment in the pre-engraftment phase of HSCT, particularly in settings where letermovir is unavailable. This strategy may reduce CMV-related graft loss while avoiding the myelotoxicity of ganciclovir. Further prospective studies are warranted to validate its role in global transplant protocols."
Beta-Thalassemia • Bone Marrow Transplantation • Cytomegalovirus Infection • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Graft versus Host Disease • Immunology • Infectious Disease • Transplantation
|
|
Santanu Sen; Nirali Sanghvi; Manam Mehra; Shyla Sen; Tanu Singhal
|